menu
    • menu
    [{"orgOrder":0,"company":"DeepCure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"DC-15442","moa":"STAT6","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"DeepCure","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DeepCure \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"DeepCure \/ Undisclosed"},{"orgOrder":0,"company":"DeepCure","sponsor":"IAG Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Series A Financing","leadProduct":"Brd4","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"DeepCure","amount2":0.02,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"DeepCure \/ IAG Capital Partners","highestDevelopmentStatusID":"2","companyTruncated":"DeepCure \/ IAG Capital Partners"},{"orgOrder":0,"company":"DeepCure","sponsor":"LIRMM","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"DC-9476","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"DeepCure","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DeepCure \/ LIRMM","highestDevelopmentStatusID":"4","companyTruncated":"DeepCure \/ LIRMM"}]

    Find Clinical Drug Pipeline Developments & Deals by DeepCure

    Menu

    DeepCure

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            DeepCure

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            DeepCure

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DC-15442

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            DeepCure Picks DC-15442 Oral STAT6 Inhibitor with Strong in Vivo Efficacy

                            Details : DC-15442 is a potent, selective, oral STAT6 inhibitor designed to replicate the safety as well as the efficacy of dupilumab, without requiring regular subcutaneous injections.

                            Product Name : DC-15442

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 10, 2025

                            Lead Product(s) : DC-15442

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            DeepCure

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            DeepCure

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DC-9476

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : LIRMM

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            DeepCure Partners with Leeds Institute To Study DC-9476 in Rheumatoid Arthritis

                            Details : The collaboration will investigate DC-9476, a third-generation selective BRD4 (BD2) inhibitor, as a potential treatment for Rheumatoid Arthritis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            August 19, 2024

                            Lead Product(s) : DC-9476

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : LIRMM

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            DeepCure

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            DeepCure

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Brd4

                            Therapeutic Area : Immunology

                            Study Phase : Discovery

                            Sponsor : IAG Capital Partners

                            Deal Size : $24.6 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            DeepCure Closes $24M Funding Round Led by IAG Capital Partners

                            Details : The net proceeds will be used to further develop DeepCure’s cutting-edge technology for small molecule drug discovery, and to advance its immunology and inflammation pipeline towards clinical trials.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            April 11, 2024

                            Lead Product(s) : Brd4

                            Therapeutic Area : Immunology

                            Highest Development Status : Discovery

                            Sponsor : IAG Capital Partners

                            Deal Size : $24.6 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth